Inclusion Criteria

DISEASE CHARACTERISTICS: Patients must be enrolled to be treated with mutated ras peptides
vaccine on another protocol Malignant disease for which no further chemotherapy or
radiation options to increase survival are available No history of CNS metastases

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:
Not specified Hematopoietic: Platelet count at least 100,000/mm3 Hepatic: Bilirubin no
greater than 2 mg/dL SGOT or SGPT no greater than 4 times normal Renal: Creatinine no
greater than 2.0 mg/dL Cardiovascular: No active ischemic heart disease (i.e., NYHA class
III or IV cardiac disease) No myocardial infarction within past 6 months No history of
congestive heart failure No ventricular arrhythmias or other arrhythmias requiring therapy
Other: HIV negative No hepatitis B or C infection No active infection requiring
antibiotics No history of autoimmune disease (e.g., autoimmune neutropenia,
thrombocytopenia, or hemolytic anemia; systemic lupus erythematosus, Sjogren syndrome, or
scleroderma; myasthenia gravis; Goodpasture syndrome; Addison's disease, Hashimoto's
thyroiditis, or active Graves' disease) No active second malignancy other than curatively
treated carcinoma in situ of the cervix or basal cell carcinoma of the skin Not pregnant
or nursing Negative pregnancy test Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy and
recovered Chemotherapy: At least 4 weeks since prior chemotherapy and recovered Endocrine
therapy: At least 4 weeks since prior steroids and recovered No concurrent steroids
Radiotherapy: At least 4 weeks since prior radiotherapy and recovered Surgery: Not
specified